Herantis Pharma Plc completes patient treatments in main study of Phase 1-2 CDNF trial in Parkinson’s disease
Herantis Pharma PlcCompany release, insider information 19 Dec 2019 at 4:00 PM Eastern European TimeHerantis Pharma Plc (“Herantis” or “Company”) announced today having completed patient treatments as planned in the main study of the Company’s Phase 1-2 clinical trial examining Herantis’ proprietary neuroprotective factor and novel drug candidate CDNF in patients with Parkinson’s disease. Of the 17 patients randomized in the clinical trial, 15 patients completed the main study according to the study protocol and two patients discontinued due to reasons not related to CDNF. All 15 patients